NSAEs · people with acute UGIH
It is very uncertain whether erythromycin changes NSAEs compared with placebo (very low certainty).
1 finding from 1 review
Rebleeding · people with acute UGIH
It is very uncertain whether erythromycin changes rebleeding compared with placebo (very low certainty).
1 finding from 1 review
Blood transfusion · people with acute UGIH
1 finding from 1 review
UGIH‐related mortality · people with acute UGIH
1 finding from 1 review
SAEs · people with acute UGIH
1 finding from 1 review
Global symptoms of dyspepsia · patients with functional dyspepsia
1 finding from 1 review
Global symptoms of dyspepsia (responders) · patients with functional dyspepsia
Curcuma longa may leads to higher global symptoms of dyspepsia (responders) compared with placebo (low certainty).
1 finding from 1 review
Adverse events Assessed clinically · patients with functional dyspepsia
Curcuma longa showed no clear difference in adverse events Assessed clinically compared with placebo (moderate certainty).
1 finding from 1 review
Quality of life · patients with functional dyspepsia
1 finding from 1 review
Global symptoms of dyspepsia (responders) · patients with functional dyspepsia
STW5 (Iberogast) showed no clear difference in global symptoms of dyspepsia (responders) compared with placebo (low certainty).
1 finding from 1 review
Adverse events Assessed clinically · patients with functional dyspepsia
STW5 (Iberogast) showed no clear difference in adverse events Assessed clinically compared with placebo (low certainty).
1 finding from 1 review
Quality of life · patients with functional dyspepsia
1 finding from 1 review
Global symptoms of dyspepsia · patients with functional dyspepsia
1 finding from 1 review
Global symptoms of dyspepsia (responders) · patients with functional dyspepsia
Peppermint/caraway oil probably leads to higher global symptoms of dyspepsia (responders) compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events Assessed clinically · patients with functional dyspepsia
Peppermint/caraway oil showed no clear difference in adverse events Assessed clinically compared with placebo (low certainty).
1 finding from 1 review
Quality of life · patients with functional dyspepsia
1 finding from 1 review
Global symptoms of dyspepsia · patients with functional dyspepsia
1 finding from 1 review
Clinical remission · people with Crohn's disease
Vedolizumab leads to higher induction of clinical remission (6–10 weeks) compared with placebo (high certainty).
1 finding from 1 review
Induction of clinical response (6–10 weeks) · people with Crohn's disease
Vedolizumab leads to higher induction of clinical response (6–10 weeks) compared with placebo (high certainty).
1 finding from 1 review
Adverse events (6–10 weeks) · people with Crohn's disease
Vedolizumab showed no clear difference in adverse events (6–10 weeks) compared with placebo (moderate certainty).
1 finding from 1 review